# Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

> **NCT02860130** · PHASE3 · TERMINATED · sponsor: **Vantive Health LLC** · enrollment: 34 (actual)

## Conditions studied

- Regional Citrate Anticoagulation (RCA)
- Continuous Renal Replacement Therapy (CRRT)
- Acute Kidney Injury

## Interventions

- **DRUG:** Prismocitrate 18
- **OTHER:** No Anticoagulation

## Key facts

- **NCT ID:** NCT02860130
- **Lead sponsor:** Vantive Health LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-27
- **Primary completion:** 2018-05-12
- **Final completion:** 2018-05-12
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Study halted due to low recruitment, unrelated to safety or efficacy reasons
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02860130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02860130, "Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02860130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*